This Policy Review summarises an expert Delphi consensus process on larynx-preservation treatments in patients affected by intermediate-to-advanced laryngeal or hypopharyngeal squamous cell carcinoma. The experts, who represented all perspectives involved in multidisciplinary management of these patients and included patient representatives, approved 137 consensus statements that cover several relevant areas in the field of larynx-preserving treatments. Statements are grouped in the following topics: granular indications for T2–T3 cancer, indications for T4a cancer, indications for salvage organ-preservation surgery after chemoradiation failure, laryngeal function at baseline, which comorbidities are contraindications and to what extent, organ preservation in older patients: selection criteria, post-treatment surveillance, prognostic and predictive factors, listening to the patient’s preferences: tools and implementation, prehabilitation and rehabilitation protocols, and cost-effectiveness of different laryngeal preservation approaches. We present a high-level summary of the results of the consensus process, with detailed reference to the full list of statements and supporting literature.

本政策综述总结了针对中晚期喉或下咽鳞状细胞癌患者喉保留治疗的专家德尔菲共识流程。专家们代表了这些患者多学科管理中的所有视角（包括患者代表），认可了137项共识声明，这些声明涵盖了喉保留治疗领域的多个相关方面。声明分为以下主题：T2-T3期癌症的细化适应症、T4a期癌症的适应症、放化疗失败后的挽救性器官保留手术适应症、基线喉功能、哪些合并症是禁忌症及禁忌症的程度、老年患者的器官保留（选择标准）、治疗后监测、预后和预测因素、关注患者偏好（工具与实施）、预康复和康复方案，以及不同喉保留方案的成本效益。本文呈现了该共识流程结果的概要，同时详细参考了完整的声明清单及支持文献。